Literature DB >> 15985754

History of surfactant from 1980.

Henry L Halliday1.   

Abstract

The first successful trial of surfactant treatment for respiratory distress syndrome (RDS) was reported in 1980. Since then there have been numerous randomised trials demonstrating first, the efficacy of surfactant treatment in reducing pulmonary air leaks and increasing survival and second, assessing various other aspects of therapy. These studies show that multiple doses may be needed if surfactant is used to treat established RDS but early or prophylactic treatment is superior for infants with gestational ages less than 30 weeks. Natural surfactants (containing proteins) are more effective than synthetic products (protein free), the latter now being infrequently used. Natural surfactants vary and should not be considered to be equivalent in their effects. A porcine surfactant (poractant alfa) acts more rapidly than a bovine preparation (beractant) in infants with moderate to severe RDS. A meta-analysis of 5 comparative studies suggests that a dose of 200 mg/kg of poractant alfa is associated with lower mortality compared with 100 mg/kg of beractant. Chronic lung disease remains a problem but it is hoped that early treatment with surfactant combined with extubation to continuous positive airway pressure will reduce this complication of prematurity. The newer synthetic surfactants, containing analogues of surfactant protein B or C, have undergone some trials for treatment of RDS but comparative studies which have just been published do not show that they are superior to existing natural surfactants. However, as they are more resistant to inactivation they may have a role in treatment of adult or acute RDS. The last 25 years have seen a large increase in basic science research on surfactants with determination of the structure and function of the four surfactant proteins probably being the most important advances. Future studies will focus on widening the indications for surfactant treatment, developing non-invasive means of administration and assessing the role of the newer synthetic surfactants. Copyright 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985754     DOI: 10.1159/000084879

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  15 in total

Review 1.  The management of postoperative reflux in congenital esophageal atresia-tracheoesophageal fistula: a systematic review.

Authors:  Anna C Shawyer; Joanne D'Souza; Julia Pemberton; Helene Flageole
Journal:  Pediatr Surg Int       Date:  2014-07-11       Impact factor: 1.827

Review 2.  Surfactant therapy: the current practice and the future trends.

Authors:  Khalid Altirkawi
Journal:  Sudan J Paediatr       Date:  2013

Review 3.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

4.  A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.

Authors:  Carlos G Guardia; Fernando R Moya; Sunil Sinha; Phillip D Simmons; Robert Segal; Jay S Greenspan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

Review 5.  Phospholipid Remodeling in Physiology and Disease.

Authors:  Bo Wang; Peter Tontonoz
Journal:  Annu Rev Physiol       Date:  2018-10-31       Impact factor: 19.318

6.  Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.

Authors:  R Ramanathan; J J Bhatia; K Sekar; F R Ernst
Journal:  J Perinatol       Date:  2011-09-01       Impact factor: 2.521

7.  Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.

Authors:  Ga Won Jeon; Minkyung Oh; Jong Beom Sin
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

8.  Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14+ Monocytes.

Authors:  Kirsten Glaser; Markus Fehrholz; Tore Curstedt; Steffen Kunzmann; Christian P Speer
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

Review 9.  What's new in surfactant? A clinical view on recent developments in neonatology and paediatrics.

Authors:  Jasper V Been; Luc J I Zimmermann
Journal:  Eur J Pediatr       Date:  2007-05-22       Impact factor: 3.183

10.  Surfactant delivery in rat lungs: Comparing 3D geometrical simulation model with experimental instillation.

Authors:  Alireza Kazemi; Bruno Louis; Daniel Isabey; Gary F Nieman; Louis A Gatto; Joshua Satalin; Sarah Baker; James B Grotberg; Marcel Filoche
Journal:  PLoS Comput Biol       Date:  2019-10-17       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.